Bridge City Capital LLC Decreases Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Bridge City Capital LLC lowered its stake in Omnicell, Inc. (NASDAQ:OMCL) by 1.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,486 shares of the company’s stock after selling 569 shares during the period. Bridge City Capital LLC owned approximately 0.09% of Omnicell worth $1,758,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC increased its position in shares of Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after purchasing an additional 273 shares during the last quarter. Van ECK Associates Corp increased its position in Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after acquiring an additional 315 shares during the last quarter. First Horizon Advisors Inc. raised its stake in shares of Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after acquiring an additional 355 shares during the period. KBC Group NV lifted its holdings in shares of Omnicell by 60.8% in the 4th quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after acquiring an additional 778 shares during the last quarter. Finally, AlphaQuest LLC boosted its stake in shares of Omnicell by 307.8% during the 4th quarter. AlphaQuest LLC now owns 3,576 shares of the company’s stock worth $159,000 after purchasing an additional 2,699 shares during the period. 97.70% of the stock is owned by institutional investors.

Omnicell Trading Down 2.7 %

NASDAQ OMCL opened at $33.94 on Friday. Omnicell, Inc. has a one year low of $25.12 and a one year high of $55.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of 125.71, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. The company’s 50-day simple moving average is $39.77 and its two-hundred day simple moving average is $42.90.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Equities analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

OMCL has been the subject of several analyst reports. Benchmark reissued a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. StockNews.com raised Omnicell from a “hold” rating to a “buy” rating in a research report on Thursday, March 6th. Bank of America reduced their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research note on Monday, January 6th. Wells Fargo & Company lowered their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $51.00.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.